KEWAUNEE SCIENTIFIC CORP /DE/ - Quarter Report: 2003 October (Form 10-Q)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
x | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended October 31, 2003
¨ | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from to
Commission file number 0-5286
KEWAUNEE SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 38-0715562 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
2700 West Front Street Statesville, North Carolina |
28677 | |
(Address of principal executive offices) | (Zip Code) |
(704) 873-7202
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
As of December 8, 2003, the Registrant had outstanding 2,486,245 shares of Common Stock.
Pages: This report, excluding exhibits, contains 19 pages numbered sequentially from this cover page.
Table of Contents
KEWAUNEE SCIENTIFIC CORPORATION
FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2003
Page Number | ||||
PART I. FINANCIAL INFORMATION |
||||
Item 1. | Financial Statements | |||
Condensed Consolidated Statements of Operations Three months and six months ended October 31, 2003 and 2002 | 3 | |||
Condensed Consolidated Balance Sheets October 31, 2003 and April 30, 2003 | 4 | |||
Condensed Consolidated Statements of Cash Flows Six months ended October 31, 2003 and 2002 | 5 | |||
Notes to Condensed Consolidated Financial Statements | 6 | |||
Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations | 10 | ||
Review by Independent Auditors | 14 | |||
Report by Independent Auditors | 15 | |||
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 16 | ||
Item 4. | Controls and Procedures | 16 | ||
PART II. OTHER INFORMATION | ||||
Item 1. | Legal Proceedings | 17 | ||
Item 4. | Submission of Matters to a Vote of Security Holders | 17 | ||
Item 6. | Exhibits and Reports on Form 8-K | 18 | ||
SIGNATURE | 19 |
Table of Contents
Part 1. Financial Information
Item 1. | Financial Statements |
Kewaunee Scientific Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
Three months ended October 31 |
Six months ended October 31 |
|||||||||||||||
2003 |
2002 |
2003 |
2002 |
|||||||||||||
($ in thousands, except per share data) | ||||||||||||||||
Net sales |
$ | 24,384 | $ | 19,905 | $ | 48,597 | $ | 39,310 | ||||||||
Cost of products sold |
20,280 | 16,762 | 40,890 | 32,726 | ||||||||||||
Gross profit |
4,104 | 3,143 | 7,707 | 6,584 | ||||||||||||
Operating expenses |
3,321 | 3,362 | 6,322 | 6,260 | ||||||||||||
Operating earnings (loss) |
783 | (219 | ) | 1,385 | 324 | |||||||||||
Interest expense |
(83 | ) | (40 | ) | (161 | ) | (82 | ) | ||||||||
Other (expense) income |
(47 | ) | 67 | 149 | 68 | |||||||||||
Earnings (loss) before income taxes |
653 | (192 | ) | 1,373 | 310 | |||||||||||
Income tax expense (benefit) |
235 | (68 | ) | 494 | 110 | |||||||||||
Net earnings (loss) |
$ | 418 | ($124 | ) | $ | 879 | $ | 200 | ||||||||
Net earnings (loss) per share- |
||||||||||||||||
Basic |
$ | 0.17 | ($0.05 | ) | $ | 0.35 | $ | 0.08 | ||||||||
Diluted |
$ | 0.17 | ($0.05 | ) | $ | 0.35 | $ | 0.08 | ||||||||
Weighted average number of common shares outstanding (in thousands)- |
||||||||||||||||
Basic |
2,486 | 2,479 | 2,485 | 2,475 | ||||||||||||
Diluted |
2,491 | 2,485 | 2,490 | 2,485 |
See accompanying notes to condensed consolidated financial statements.
3
Table of Contents
Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
(in thousands)
October 31 2003 |
April 30 2003 |
|||||||
(Unaudited) | ||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 796 | $ | 520 | ||||
Receivables, less allowance |
21,930 | 16,138 | ||||||
Inventories |
4,740 | 5,958 | ||||||
Deferred income taxes |
103 | 89 | ||||||
Prepaid income taxes |
422 | 1,499 | ||||||
Prepaid expenses and other current assets |
908 | 782 | ||||||
Total current assets |
28,899 | 24,986 | ||||||
Property, plant and equipment, at cost |
33,142 | 31,926 | ||||||
Accumulated depreciation |
(21,177 | ) | (20,135 | ) | ||||
Net property, plant and equipment |
11,965 | 11,791 | ||||||
Other assets |
6,461 | 6,877 | ||||||
Total Assets |
$ | 47,325 | $ | 43,654 | ||||
Liabilities and Stockholders Equity |
||||||||
Current liabilities: |
||||||||
Short-term borrowings |
$ | 4,740 | $ | 1,416 | ||||
Current portion of long-term debt |
1,118 | 681 | ||||||
Accounts payable |
5,558 | 8,338 | ||||||
Employee compensation and amounts withheld |
1,444 | 1,203 | ||||||
Deferred Revenue |
1,740 | 856 | ||||||
Other accrued expenses |
1,399 | 834 | ||||||
Total current liabilities |
15,999 | 13,328 | ||||||
Long-term debt |
1,490 | 1,249 | ||||||
Deferred income taxes |
1,151 | 1,150 | ||||||
Accrued employee benefit plan costs |
1,657 | 1,634 | ||||||
Other long-term liabilities |
495 | 355 | ||||||
Total Liabilities |
20,792 | 17,716 | ||||||
Stockholders equity: |
||||||||
Common stock |
6,550 | 6,550 | ||||||
Additional paid-in-capital |
134 | 145 | ||||||
Retained earnings |
20,641 | 20,110 | ||||||
Accumulated other comprehensive income (loss) |
32 | (9 | ) | |||||
Common stock in treasury, at cost |
(824 | ) | (858 | ) | ||||
Total stockholders equity |
26,533 | 25,938 | ||||||
Total Liabilities and Stockholders Equity |
$ | 47,325 | $ | 43,654 | ||||
See accompanying notes to condensed financial statements.
4
Table of Contents
Kewaunee Scientific Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Six months ended October 31 |
||||||||
2003 |
2002 |
|||||||
Cash flows from operating activities: |
||||||||
Net earnings |
$ | 879 | $ | 200 | ||||
Adjustments to reconcile net earnings to net cash used in operating activities: |
||||||||
Depreciation |
1,041 | 1,434 | ||||||
Provision for bad debts |
6 | 82 | ||||||
Decrease in prepaid income taxes |
1,077 | 95 | ||||||
Increase in receivables |
(5,798 | ) | (1,030 | ) | ||||
Decrease in inventories |
1,218 | 256 | ||||||
Decrease in accounts payable and other current liabilities |
(1,974 | ) | (93 | ) | ||||
Increase in deferred revenue |
884 | 13 | ||||||
Other, net |
481 | 72 | ||||||
Net cash (used in) provided by operating activities |
(2,186 | ) | 1,029 | |||||
Cash flows from investing activities: |
||||||||
Capital expenditures |
(1,215 | ) | (2,362 | ) | ||||
Proceeds from sale of fixed assets |
| 366 | ||||||
Net cash used in investing activities |
(1,215 | ) | (1,996 | ) | ||||
Cash flows from financing activities: |
||||||||
Increase in short-term borrowings |
3,324 | 346 | ||||||
Proceeds from long-term debt |
1,200 | | ||||||
Payments on long-term debt |
(522 | ) | (340 | ) | ||||
Dividends paid |
(348 | ) | (347 | ) | ||||
Proceeds from exercise of stock options (including tax benefit) |
23 | 45 | ||||||
Net cash provided by (used in) financing activities |
3,677 | (296 | ) | |||||
Increase (decrease) in cash and cash equivalents |
276 | 1,263 | ||||||
Cash and cash equivalents, beginning of period |
520 | 1,747 | ||||||
Cash and cash equivalents, end of period |
$ | 796 | $ | 484 | ||||
See accompanying notes to condensed financial statements.
5
Table of Contents
Kewaunee Scientific Corporation
Notes to Condensed Consolidated Financial Statements
(unaudited)
A. | Financial Information |
The unaudited interim condensed consolidated financial statements of Kewaunee Scientific Corporation (the Company or Kewaunee) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the Commission). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Companys 2003 Annual Report to Stockholders.
The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the interim periods. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
Certain prior quarterly accounts have been reclassified with current quarterly presentations.
B. | Inventories |
Inventories consisted of the following (in thousands):
October 31, 2003 |
April 30, 2003 | |||||
Finished products |
$ | 1,909 | $ | 2,402 | ||
Work in process |
1,742 | 1,812 | ||||
Raw materials |
1,089 | 1,744 | ||||
$ | 4,740 | $ | 5,958 | |||
6
Table of Contents
C. | Balance Sheet |
The Companys April 30, 2003 condensed consolidated balance sheet as presented herein is derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles.
D. | Segment Information |
The following table shows net sales and profits by business segment for three months and six months ended October 31, 2003 and 2002 (in thousands):
Laboratory Products |
Technical Products |
Corporate |
Total |
|||||||||||
Three months ended October 31, 2003 |
||||||||||||||
Revenues from external customers |
$ | 22,741 | $ | 1,643 | | $ | 24,384 | |||||||
Intersegment revenues |
377 | | (377 | ) | | |||||||||
Segment profit (loss) |
1,028 | 40 | (415 | ) | 653 | |||||||||
Segment Assets |
42,731 | | 4,594 | 47,325 | ||||||||||
Three months ended October 31, 2002 |
||||||||||||||
Revenues from external customers |
$ | 18,231 | $ | 1,674 | | $ | 19,905 | |||||||
Intersegment revenues |
183 | | (183 | ) | | |||||||||
Segment profit (loss) |
255 | 72 | (519 | ) | (192 | ) | ||||||||
Segment Assets |
39,799 | | 2,258 | 42,057 | ||||||||||
Six months ended October 31, 2003 |
||||||||||||||
Revenues from external customers |
$ | 45,342 | $ | 3,255 | | $ | 48,597 | |||||||
Intersegment revenues |
1,419 | | (1,419 | ) | | |||||||||
Segment profit (loss) |
1,902 | 123 | (652 | ) | 1,373 | |||||||||
Segment Assets |
42,731 | | 4,594 | 47,325 | ||||||||||
Six months ended October 31, 2002 |
||||||||||||||
Revenues from external customers |
$ | 36,279 | $ | 3,031 | | $ | 39,310 | |||||||
Intersegment revenues |
345 | | (345 | ) | | |||||||||
Segment profit (loss) |
1,123 | (44 | ) | (769 | ) | 310 | ||||||||
Segment Assets |
39,799 | | 2,258 | 42,057 |
7
Table of Contents
E. | Comprehensive Income |
A reconciliation of net earnings and total comprehensive income for the three months and six months ended October 31, 2003 and 2002 is as follows (in thousands):
Three months ended October 31, 2003 |
Three months ended October 31, 2002 |
||||||
Net earnings (loss) |
$ | 418 | $ | (124 | ) | ||
Change in fair value of cash flow hedge, net of income tax |
3 | (8 | ) | ||||
Change in cumulative foreign currency translation adjustments |
16 | (2 | ) | ||||
Total comprehensive income (loss) |
$ | 437 | $ | (134 | ) | ||
Six months ended October 31, 2003 |
Six months ended October 31, 2002 |
||||||
Net earnings |
$ | 879 | $ | 200 | |||
Change in fair value of cash flow hedge, net of income tax |
9 | (37 | ) | ||||
Change in cumulative foreign currency translation adjustments |
33 | 18 | |||||
Total comprehensive income |
$ | 921 | $ | 181 |
The Company adopted SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, effective January 1, 2001. SFAS No. 133 requires that the Company record derivatives on the balance sheet at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Companys business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company may from time-to-time employ derivative financial instruments, such as interest rate swap contracts, to mitigate or eliminate certain of those risks. The Company does not enter into derivative instruments for speculative purposes. The Company had one interest rate swap agreement outstanding at October 31, 2003.
For the Companys foreign subsidiaries, assets and liabilities are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders equity.
8
Table of Contents
F. | Commitments and Contingencies |
The Company is involved in a legal dispute with Bernards Bros. Inc., a former customer of the Company. The dispute was the subject of lengthy arbitration proceedings completed in December 2000. In June 2003, a judgment was entered in the case against the Company and two other defendants identifying the responsibility for the payment of the Arbitrators award. The Company believes that its ultimate liability regarding this matter ranges from $100,000 to $400,000. At October 31, 2003, the Company had an accrual of $134,000 for final settlement of this matter, unchanged from April 30, 2003.
G. | Stock Options |
The Company accounts for stock options granted to employees and directors using the intrinsic value method. Under this method no compensation expense is recorded since the exercise price of the stock options is equal to the market price of the underlying stock on the grant date. Had compensation expense for the stock options issued been determined consistent with Financial Accounting Standards Board (FASB) Statement No. 123, Accounting for Stock-Based Compensation, net earnings and net earnings per share would have been reduced to the following pro forma amounts (in thousands, except per share data):
Three months ended October 31, 2003 |
Three months ended October 31, 2002 |
|||||||
Net earnings (loss) as reported |
$ | 418 | $ | (124 | ) | |||
Pro forma compensation cost |
(20 | ) | (27 | ) | ||||
Net earnings (loss) pro forma |
398 | (151 | ) | |||||
Net earnings (loss) per share Basic |
||||||||
As reported |
$ | 0.17 | $ | (0.05 | ) | |||
Pro forma |
0.16 | (0.06 | ) | |||||
Net earnings (loss) per share Diluted |
||||||||
As reported |
$ | 0.17 | $ | (0.05 | ) | |||
Pro forma |
0.16 | (0.06 | ) | |||||
Six months ended October 31, 2003 |
Six months ended October 31, 2002 |
|||||||
Net earnings as reported |
$ | 879 | $ | 200 | ||||
Pro forma compensation cost |
(40 | ) | (54 | ) | ||||
Net earnings pro forma |
839 | 146 | ||||||
Net earnings per share Basic |
||||||||
As reported |
$ | 0.35 | $ | 0.08 | ||||
Pro forma |
0.34 | 0.06 | ||||||
Net earnings per share Diluted |
||||||||
As reported |
$ | 0.35 | $ | 0.08 | ||||
Pro forma |
0.34 | 0.06 |
9
Table of Contents
Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations |
The Companys 2003 Annual Report to Stockholders contains managements discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2003. The following discussion and analysis describes material changes in the Companys financial condition since April 30, 2003. The analysis of results of operations compares the three months and six months ended October 31, 2003 with the comparable periods of the prior fiscal year.
Results of Operations
The Company recorded sales of $24.4 million for the three months ended October 31, 2003, up 22.5% from sales of $19.9 million for the comparable period of the prior year. Sales for the six months ended October 31, 2003 were $48.6 million, up 23.6% from sales of $39.3 million in the comparable period of the prior year.
Sales of laboratory products increased 24.7% and 25.0% during the three months and six months ended October 31, 2003, respectively, from the same periods last year, while sales of technical products decreased 1.9% and increased 7.4%, respectively. Strong sales were experienced for all of the Companys major laboratory product lines. The order backlog was $46.3 million at October 31, 2003, compared to $36.9 million at October 31, 2002.
The gross profit margin for the three months ended October 31, 2003 was 16.8% of sales, as compared to 15.8% of sales in the comparable quarter of the prior year. The gross profit margin for the six months ended October 31, 2003 was 15.9%, as compared to 16.7% in the comparable period of the prior year. Gross profit margins for the three and six months periods of the current year were adversely affected by pricing pressures in the markets for the Companys products. The gross profit margin for the six months period of the current year was also adversely affected by manufacturing inefficiencies in the first quarter of the year. The gross profit in the prior year periods were adversely affected by $550,000 in charges related to the relocation of the Companys technical products business and write-down of related inventories.
10
Table of Contents
Operating expenses for the three months ended October 31, 2003 were $3.3 million, or 13.6% of sales, as compared to $3.4 million, or 16.9% of sales, in the comparable period of the prior year. Included in the current quarter were charges of $144,000 for severance costs and included in the prior year quarter were charges of $179,000 related to the relocation of the Companys technical products business. Operating expenses for the six months ended October 31, 2003 were $6.3 million, or 13.0% of sales, as compared to $6.3 million, or 15.9% of sales, in the comparable period of the prior year. The improved ratio of expenses to sales in the current year occurred as operating expenses remained relatively flat while sales increased.
Interest expense was $83,000 and $161,000 for the three months and six months ended October 31, 2003, respectively, compared to $40,000 and $82,000 for the comparable periods of the prior year. The increase in interest expense for the current quarter and year resulted from higher levels of borrowings.
Other expense was $47,000 and other income was $149,000 in the three months and six months ended October 31, 2003, respectively, compared to other income of $67,000 and $68,000 for the comparable periods of the prior year. Other income for the current year was increased by $295,000 in the first quarter from the resolution of a disputed claim for laboratory furniture sold by the Company several years ago.
Income tax expenses of $235,000 and $494,000 were recorded for the three months and six months ended October 31, 2003, respectively, as compared to an income tax benefit of $68,000 and an income tax expense of $110,000 recorded for the comparable periods of the prior year. The effective tax rate was approximately 36.0% for the three and six months ended October 31, 2003 and 35.5% for the three and six months period ended October 31, 2002.
11
Table of Contents
Net earnings of $418,000 and $879,000, or $.17 per diluted share and $.35 per diluted share, were recorded for the three months and six months ended October 31, 2003, respectively. This compares to a net loss of $124,000 and net earnings of $200,000, or $.05 per diluted share and $.08 per diluted share, respectively, for the comparable periods of the prior year.
Liquidity and Capital Resources
Historically, the Companys principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings. The Company believes that these sources, will be sufficient to support ongoing business levels, including capital expenditures through the current fiscal year.
During the first quarter of the current year, the Companys revolving credit loan was amended to increase allowable advances under the loan from $7.0 million to $9.0 million. At October 31, 2003, advances of $4,740,000 were outstanding under this loan. During the first quarter of the current year, the Company increased its long-term bank borrowings by $1.2 million, with such borrowings repayable in thirty-three equal monthly installments.
The Company had working capital of $12.9 million at October 31, 2003, as compared to $11.7 million at April 30, 2003. The ratio of current assets to current liabilities was 1.8-to-1 at October 31, 2003, as compared to 1.9-to-1 at April 30, 2003.
The Companys operations used cash of $2.2 million during the six months ended October 31, 2003, primarily attributable to an increase in accounts receivable and a decrease in accounts payable, partially offset by reductions in prepaid income taxes and inventories. The Companys operations provided cash of $1.0 million during six months ended October 31, 2002, primarily from operating earnings, partially offset by an increase in accounts receivable.
During the six months ended October 31, 2003, the Company used net cash of $1,215,000 in investing activities, primarily for production equipment, compared to $1,996,000 for such expenditures in the comparable period of the prior year.
12
Table of Contents
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995
Certain statements in this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Reform Act). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Companys operations, markets, products, services, and prices. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of the Reform Act. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms believes, belief, expects, plans, objectives, anticipates, intends or the like to be uncertain and forward-looking.
13
Table of Contents
REVIEW BY INDEPENDENT AUDITORS
A review of the interim financial information included in this Quarterly Report on Form 10-Q for the three months and six months ended October 31, 2003 has been performed by PricewaterhouseCoopers LLP, the Companys independent auditors. Their report on the interim financial information follows.
14
Table of Contents
REPORT OF INDEPENDENT AUDITORS
To the Board of Directors and Stockholders of
Kewaunee Scientific Corporation
Statesville, North Carolina
We have reviewed the accompanying condensed consolidated balance sheet of Kewaunee Scientific Corporation as of October 31, 2003 and April 30, 2003, and the related condensed consolidated statements of operations for each of the three and six-month periods ended October 31, 2003 and October 31, 2002 and the condensed consolidated statement of cash flows for the six-month periods ended October 31, 2003 and October 31, 2002. These financial statements are the responsibility of the Companys management.
We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should be made to the accompanying condensed consolidated interim financial information for them to be in conformity with accounting principles generally accepted in the United States of America.
We previously audited in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet as of April 30, 2003, and the related consolidated statements of operations, of stockholders equity, and of cash flows for the year then ended (not presented herein), and in our report dated June 4, 2003 we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of April 30, 2003 is fairly stated in all material respects in relation to the consolidated balance sheet from which it has been derived.
PricewaterhouseCoopers LLP
Charlotte, North Carolina
November 21, 2003
15
Table of Contents
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
There are no material changes to the disclosures made on this matter in the Companys Annual Report on Form 10-K for the fiscal year ended April 30, 2003.
Item 4. | Controls and Procedures |
(a) | Evaluation of disclosure controls and procedures |
An evaluation was performed under the supervision and the participation of the companys management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of the Companys disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of October 31, 2003. Based on that evaluation, the Companys management, including the CEO and CFO, concluded that, as of October 31, 2003, the Companys disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.
(b) | Changes in internal controls |
There were no significant changes in the Companys internal controls or in other factors that could significantly affect these controls subsequent to October 31, 2003. As no significant deficiencies or material weaknesses were found, no corrective actions were taken.
16
Table of Contents
PART II. OTHER INFORMATION
Item 1. | Legal Proceedings |
The Company is involved in a legal dispute with Bernards Bros. Inc., a former customer of the Company. The dispute was the subject of lengthy arbitration proceedings completed in December 2000. In June 2003, a judgment was entered in the case against the Company and two other defendants identifying the responsibility for the payment of the Arbitrators award. The Company believes that its ultimate liability regarding this matter ranges from $100,000 to $400,000. At October 31, 2003, the Company had an accrual of $134,000 for final settlement of this matter, unchanged from April 30, 2003.
Item 4. | Submission of Matters to a Vote of Security Holders |
The Companys Annual Meeting of Stockholders was held on August 27, 2003. Information regarding the results of this meeting are incorporated by reference from the Companys Report on Form 10-Q for the three months ended July 31, 2003.
17
Table of Contents
Item 6. | Exhibits and Reports on Form 8-K |
(a) | Exhibits |
31.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
(b) | Reports on Form 8-K |
A Form 8-K was filed on August 25, 2003 with the Commission which included as an exhibit the Companys Press Release announcing the financial results for the three months ended July 31, 2003.
18
Table of Contents
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KEWAUNEE SCIENTIFIC CORPORATION | ||||||||
(Registrant) | ||||||||
Date: December 15, 2003 | By | /s/ D. MICHAEL PARKER | ||||||
D. Michael Parker Senior Vice President, Finance and Chief Financial Officer |
19